TY - JOUR
T1 - Influence of Risk on Reduction of Readmission and Death by Disease Management Programs in Heart Failure
AU - Huynh, Quan L.
AU - Whitmore, Kristyn
AU - Negishi, Kazuaki
AU - Marwick, Thomas H.
AU - on behalf of the ETHELRED Investigators
N1 - Funding Information:
Funding: Supported in part by a partnership grant from the National Health and Medical Research Foundation (Canberra), Tasmania Medicare Local (Hobart), Department of Health and Human Services (Hobart), and National Heart Foundation of Australia (Canberra). Funding: Supported in part by a partnership grant from the National Health and Medical Research Foundation (Canberra), Tasmania Medicare Local (Hobart), Department of Health and Human Services (Hobart), and National Heart Foundation of Australia (Canberra). Trial registration information: Australia and New Zealand Clinical Trials Registry (anzctr.org.au), ACTRN12616001303437. Menzies Institute for Medical Research, Hobart, Australia: Quan Huynh, PhD, Kristyn Whitmore, BSN, and Thomas Marwick, MBBS, PhD, MPH. Royal Hobart Hospital, Hobart, Australia: Paul McIntyre, MD, Nathan Dwyer, MD, PhD, and Sue Sanderson, MNSc. Launceston General Hospital: Brian Herman, MD, and Elizabeth Gordon, BSN, MBA. Funding: Supported in part by a partnership grant from the National Health and Medical Research Foundation (Canberra), Tasmania Medicare Local (Hobart), Department of Health and Human Services (Hobart), and National Heart Foundation of Australia (Canberra). Trial registration information: Australia and New Zealand Clinical Trials Registry (anzctr.org.au), ACTRN12616001303437.
Funding Information:
Funding: Supported in part by a partnership grant from the National Health and Medical Research Foundation (Canberra), Tasmania Medicare Local (Hobart), Department of Health and Human Services (Hobart), and National Heart Foundation of Australia (Canberra).
Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/5
Y1 - 2019/5
N2 - Objective: Disease management programs (DMPs) may reduce short-term readmission or death after heart failure (HF) hospitalization. We sought to determine if targeting of DMP to the highest-risk patients could improve efficiency. Methods and Results: Patients (n = 412) admitted with HF were randomized to usual care or an intensive DMP including optimizing intravascular volume status at discharge, increased self-care education, exercise guidance, closer home surveillance, and increased intensity of HF nurse follow-up. Both treatment groups were similar in demographics, medication use, Charlson comorbidity index, ejection fraction, and left ventricular and atrial volumes. Readmission or death occurred in 74/197 (37%) usual care and 50/215 (23%) DMP patients within 30 days (relative risk [RR] 0.62, 95% confidence interval [CI] 0.46–0.84), and 113/197 (57%) usual care and 78/215 (36%) DMP patients within 90 days, (RR 0.63, 9%% CI 0.51–0.78). The predicted risk of death and readmission (estimated from our previously developed risk score) was similar between treatment groups (mean predicted risk 38.6 ± 22.2% vs 39.4 ± 21.9%; P = .73) and similar across categories of predicted risk between the treatment groups. For 30-day readmission or death, patients from the 2 highest risk quintiles showed a benefit from intervention, and there was an interaction between intervention and predicted risk (P = .02). For 90-day readmission or death, most patients—other than those in the lowest-risk quintile—benefited from the intervention. Conclusions: Use of a risk score may permit targeting of DMP to reduce HF admission. Intensive DMP may reduce short-term readmission or death, particularly in high-risk patients.
AB - Objective: Disease management programs (DMPs) may reduce short-term readmission or death after heart failure (HF) hospitalization. We sought to determine if targeting of DMP to the highest-risk patients could improve efficiency. Methods and Results: Patients (n = 412) admitted with HF were randomized to usual care or an intensive DMP including optimizing intravascular volume status at discharge, increased self-care education, exercise guidance, closer home surveillance, and increased intensity of HF nurse follow-up. Both treatment groups were similar in demographics, medication use, Charlson comorbidity index, ejection fraction, and left ventricular and atrial volumes. Readmission or death occurred in 74/197 (37%) usual care and 50/215 (23%) DMP patients within 30 days (relative risk [RR] 0.62, 95% confidence interval [CI] 0.46–0.84), and 113/197 (57%) usual care and 78/215 (36%) DMP patients within 90 days, (RR 0.63, 9%% CI 0.51–0.78). The predicted risk of death and readmission (estimated from our previously developed risk score) was similar between treatment groups (mean predicted risk 38.6 ± 22.2% vs 39.4 ± 21.9%; P = .73) and similar across categories of predicted risk between the treatment groups. For 30-day readmission or death, patients from the 2 highest risk quintiles showed a benefit from intervention, and there was an interaction between intervention and predicted risk (P = .02). For 90-day readmission or death, most patients—other than those in the lowest-risk quintile—benefited from the intervention. Conclusions: Use of a risk score may permit targeting of DMP to reduce HF admission. Intensive DMP may reduce short-term readmission or death, particularly in high-risk patients.
KW - Heart failure
KW - intervention
KW - mortality
KW - readmission
KW - risk score
UR - https://www.scopus.com/pages/publications/85062217454
U2 - 10.1016/j.cardfail.2019.01.015
DO - 10.1016/j.cardfail.2019.01.015
M3 - Article
C2 - 30716400
AN - SCOPUS:85062217454
SN - 1071-9164
VL - 25
SP - 330
EP - 339
JO - Journal of Cardiac Failure
JF - Journal of Cardiac Failure
IS - 5
ER -